These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 32752585)

  • 21. Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis.
    Gao W; Wu L; Jin S; Li J; Liu X; Xu J; Zhang W; Gong Q; Sun C; Wang W; Wang Z; Shao YW; Yin JC; Shen L; Chen L; Wang Q; Guo R
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors.
    Kaira K; Mouri A; Imai H; Yamaguchi O; Kagamu H
    Curr Oncol Rep; 2024 Sep; 26(9):1113-1119. PubMed ID: 38954314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical spectrum of neuromuscular complications after immune checkpoint inhibition.
    Puwanant A; Isfort M; Lacomis D; Živković SA
    Neuromuscul Disord; 2019 Feb; 29(2):127-133. PubMed ID: 30638612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pembrolizumab-induced myasthenia gravis: A fatal case report.
    March KL; Samarin MJ; Sodhi A; Owens RE
    J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Myasthenia gravis associated with nivolumab].
    Miñón-Fernández B; Losada-Domingo JM; Sánchez-Horvath MT; Bárcena-Llona J
    Rev Neurol; 2020 Jan; 70(2):72-73. PubMed ID: 31930473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
    Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
    Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
    Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
    Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies.
    Salim A; Tapia Rico G; Shaikh A; Brown MP
    Expert Opin Biol Ther; 2021 Sep; 21(9):1237-1251. PubMed ID: 33645372
    [No Abstract]   [Full Text] [Related]  

  • 29. Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis.
    Moradi LA; Clark CA; Schneider CS; Deshane AS; Dobelbower MC
    Front Immunol; 2021; 12():788499. PubMed ID: 34956219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
    Gambichler T; Doerler M; Scheel CH
    Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
    [No Abstract]   [Full Text] [Related]  

  • 31. [A case of myasthenia gravis and myositis induced by pembrolizumab].
    Noda T; Kageyama H; Miura M; Tamura T; Ito H
    Rinsho Shinkeigaku; 2019 Aug; 59(8):502-508. PubMed ID: 31341124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases].
    Reyes-Bueno JA; Rodriguez-Santos L; Serrano-Castro PJ
    Rev Neurol; 2019 Apr; 68(8):333-338. PubMed ID: 30963530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at national cancer center in Korea.
    Hyun JW; Kim KH; Kim SH; Kim HJ
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):5583-5589. PubMed ID: 36495331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical features of immune checkpoint inhibitor-related myositis in patients with urological cancer].
    Ying YC; Tang Q; Yang KW; Mi Y; Fan Y; Yu W; Song Y; He ZS; Zhou LQ; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):644-651. PubMed ID: 35950386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.
    Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H
    Immunotherapy; 2022 May; 14(7):511-520. PubMed ID: 35321560
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.
    Gao L; Li X; Guo Z; Tang L; Peng J; Liu B
    Medicine (Baltimore); 2022 Dec; 101(49):e32240. PubMed ID: 36626474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment.
    Psimaras D; Velasco R; Birzu C; Tamburin S; Lustberg M; Bruna J; Argyriou AA
    J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S74-S85. PubMed ID: 31393660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
    Prevel R; Colin G; Calès V; Renault PA; Mazieres J
    Rev Med Interne; 2020 Apr; 41(4):284-288. PubMed ID: 31983550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy.
    Schweizer C; Schubert P; Rutzner S; Eckstein M; Haderlein M; Lettmaier S; Semrau S; Gostian AO; Frey B; Gaipl US; Zhou JG; Fietkau R; Hecht M
    Eur J Cancer; 2020 Nov; 140():55-62. PubMed ID: 33045663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.